Literature DB >> 25224567

Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.

William E Fantegrossi1, Bradley W Gray, Jessica M Bailey, Douglas A Smith, Martin Hansen, Jesper L Kristensen.   

Abstract

RATIONALE: 2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]methyl)phenol (25CN-NBOH) is structurally similar to N-benzyl substituted phenethylamine hallucinogens currently emerging as drugs of abuse. 25CN-NBOH exhibits dramatic selectivity for 5-HT2A receptors in vitro, but has not been behaviorally characterized.
OBJECTIVE: 25CN-NBOH was compared to the traditional phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) using mouse models of drug-elicited head twitch behavior and drug discrimination.
METHODS: Drug-elicited head twitches were quantified for 10 min following administration of various doses of either DOI or 25CN-NBOH, with and without pretreatments of 0.01 mg/kg 5-HT2A antagonist M100907 or 3.0 mg/kg 5-HT2C antagonist RS102221. The capacity of 25CN-NBOH to attenuate DOI-elicited head twitch was also investigated. Mice were trained to discriminate DOI or M100907 from saline, and 25CN-NBOH was tested for generalization.
RESULTS: 25CN-NBOH induced a head twitch response in the mouse that was lower in magnitude than that of DOI, blocked by M100907, but not altered by RS102221. DOI-elicited head twitch was dose-dependently attenuated by 25CN-NBOH pretreatment. 25CN-NBOH produced an intermediate degree of generalization (55 %) for the DOI training dose, and these interoceptive effects were attenuated by M100907. Finally, 25CN-NBOH did not generalize to M100907 at any dose, but ketanserin fully substituted in these animals.
CONCLUSIONS: 25CN-NBOH was behaviorally active, but less effective than DOI in two mouse models of hallucinogenic effects. The effectiveness with which M100907 antagonized the behavioral actions of 25CN-NBOH strongly suggests that the 5-HT2A receptor is an important site of agonist action for this compound in vivo.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224567      PMCID: PMC4339409          DOI: 10.1007/s00213-014-3739-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.

Authors:  Thomas H McLean; Jason C Parrish; Michael R Braden; Danuta Marona-Lewicka; Alejandra Gallardo-Godoy; David E Nichols
Journal:  J Med Chem       Date:  2006-09-21       Impact factor: 7.446

3.  Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.

Authors:  Michael R Braden; Jason C Parrish; John C Naylor; David E Nichols
Journal:  Mol Pharmacol       Date:  2006-09-25       Impact factor: 4.436

4.  High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.

Authors:  David E Nichols; Stewart P Frescas; Benjamin R Chemel; Kenneth S Rehder; Desong Zhong; Anita H Lewin
Journal:  Bioorg Med Chem       Date:  2008-04-25       Impact factor: 3.641

Review 5.  5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function.

Authors:  B L Roth; D L Willins; K Kristiansen; W K Kroeze
Journal:  Pharmacol Ther       Date:  1998-09       Impact factor: 12.310

6.  A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor.

Authors:  M A Parker; D Marona-Lewicka; V L Lucaites; D L Nelson; D E Nichols
Journal:  J Med Chem       Date:  1998-12-17       Impact factor: 7.446

7.  Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.

Authors:  W E Fantegrossi; J Simoneau; M S Cohen; S M Zimmerman; C M Henson; K C Rice; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  2010-09-21       Impact factor: 4.030

Review 8.  Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.

Authors:  Antoni R Blaazer; Pieter Smid; Chris G Kruse
Journal:  ChemMedChem       Date:  2008-09       Impact factor: 3.466

9.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

10.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats.

Authors:  Jun-Xu Li; Alison Unzeitig; Martin A Javors; Kenner C Rice; Wouter Koek; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2009-08-17       Impact factor: 4.030

View more
  15 in total

1.  Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Authors:  Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2018-09-25       Impact factor: 5.858

2.  Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.

Authors:  Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell
Journal:  Psychopharmacology (Berl)       Date:  2018-11-17       Impact factor: 4.530

3.  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.

Authors:  Kuglae Kim; Tao Che; Ouliana Panova; Jeffrey F DiBerto; Jiankun Lyu; Brian E Krumm; Daniel Wacker; Michael J Robertson; Alpay B Seven; David E Nichols; Brian K Shoichet; Georgios Skiniotis; Bryan L Roth
Journal:  Cell       Date:  2020-09-17       Impact factor: 41.582

4.  Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Authors:  Joshua S Elmore; Ann M Decker; Agnieszka Sulima; Kenner C Rice; John S Partilla; Bruce E Blough; Michael H Baumann
Journal:  Neuropharmacology       Date:  2018-03-01       Impact factor: 5.250

Review 5.  Effect of Hallucinogens on Unconditioned Behavior.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2018

6.  Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice.

Authors:  Adam L Halberstadt; Muhammad Chatha; Stephen J Chapman; Simon D Brandt
Journal:  J Psychopharmacol       Date:  2019-02-21       Impact factor: 4.153

7.  Automated Computer Software Assessment of 5-Hydroxytryptamine 2A Receptor-Mediated Head Twitch Responses from Video Recordings of Mice.

Authors:  Grant C Glatfelter; Michael R Chojnacki; Shelby A McGriff; Tianpeng Wang; Michael H Baumann
Journal:  ACS Pharmacol Transl Sci       Date:  2022-04-08

8.  Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice.

Authors:  Adam L Halberstadt; Ivan S Sindhunata; Kees Scheffers; Aaron D Flynn; Richard F Sharp; Mark A Geyer; Jared W Young
Journal:  Neuropharmacology       Date:  2016-03-25       Impact factor: 5.250

Review 9.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.